Premium
Gastrointestinal stromal tumors: Treatment patterns of a population‐based sample
Author(s) -
Harlan Linda C.,
Eisenstein Jana,
Russell Maria C.,
Stevens Jennifer L.,
Cardona Kenneth
Publication year - 2015
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23879
Subject(s) - medicine , gist , adjuvant therapy , population , imatinib , cancer , adjuvant , multivariate analysis , imatinib mesylate , disease , oncology , surgery , stromal cell , environmental health , myeloid leukemia
Objectives The National Cancer Institute (NCI) annually confirms therapy with treating physicians on a sample of patients diagnosed with a specific cancer. Methods Using the NCI Patterns of Care data, treatment patterns were examined on a population‐based sample of patients diagnosed with gastrointestinal stromal tumors (GIST) in 2008. Results A random sample of 323 of 405 GIST patients registered in SEER was selected. Most patients had gastric GISTs, were ≥65 years, white, had private insurance, and treated in a hospital with a residency program. Surgery was primarily performed in patients with non‐metastatic disease (94%), in which: 26, 12, and 36% were at low, intermediate, and high‐risk of recurrence, respectively. Amongst low‐risk patients, ∼30% received adjuvant therapy. Amongst patients at higher risk, 26–40% did not receive adjuvant therapy. Imatinib was the most common targeted therapy administered. On multivariate analysis, age and risk‐group were associated with receipt of adjuvant targeted therapy. Conclusions Our study shows that in 2008, the majority of patients diagnosed with GIST received appropriate surgical and adjuvant therapies. However, a considerable subset may have been overtreated and undertreated. Future studies identifying factors that impact the delivery of adjuvant therapy should be conducted. J. Surg. Oncol. 2015 111:702–707 . © 2015 Wiley Periodicals, Inc.